CRIS Current Research Information System

VERUCCHI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.042
AS - Asia 6.697
EU - Europa 5.935
SA - Sud America 436
AF - Africa 395
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 22.520
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.968
SG - Singapore 1.940
GB - Regno Unito 1.927
VN - Vietnam 1.833
CN - Cina 1.560
DE - Germania 736
IT - Italia 720
SE - Svezia 703
HK - Hong Kong 431
FR - Francia 412
IN - India 361
RU - Federazione Russa 323
BR - Brasile 321
UA - Ucraina 318
IE - Irlanda 218
ZA - Sudafrica 124
NL - Olanda 112
JP - Giappone 110
EE - Estonia 106
CI - Costa d'Avorio 97
FI - Finlandia 97
TG - Togo 84
BG - Bulgaria 58
AR - Argentina 56
KR - Corea 56
PH - Filippine 48
JO - Giordania 46
BD - Bangladesh 39
CA - Canada 39
CH - Svizzera 37
TH - Thailandia 37
IQ - Iraq 32
ID - Indonesia 31
ES - Italia 30
AT - Austria 29
PK - Pakistan 26
SC - Seychelles 25
MX - Messico 24
TW - Taiwan 24
TR - Turchia 23
NG - Nigeria 21
PL - Polonia 21
GR - Grecia 18
EC - Ecuador 17
BE - Belgio 16
UZ - Uzbekistan 15
IR - Iran 11
LB - Libano 11
MA - Marocco 11
AU - Australia 9
CL - Cile 9
SA - Arabia Saudita 9
VE - Venezuela 9
CO - Colombia 8
EG - Egitto 8
IL - Israele 8
LT - Lituania 8
DK - Danimarca 7
PE - Perù 7
LU - Lussemburgo 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
MY - Malesia 5
OM - Oman 5
PS - Palestinian Territory 5
PY - Paraguay 5
AO - Angola 4
CZ - Repubblica Ceca 4
ET - Etiopia 4
KE - Kenya 4
KZ - Kazakistan 4
NP - Nepal 4
PT - Portogallo 4
A2 - ???statistics.table.value.countryCode.A2??? 3
DZ - Algeria 3
PA - Panama 3
RS - Serbia 3
SN - Senegal 3
TN - Tunisia 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
GA - Gabon 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
Totale 22.503
Salva come PNG Salva come JPEG
Città #
Southend 1.770
Singapore 1.326
Ashburn 977
Fairfield 964
Chandler 658
Houston 486
Woodbridge 469
Seattle 439
Wilmington 426
Ho Chi Minh City 417
Hong Kong 407
San Jose 403
Hanoi 360
Santa Clara 343
Cambridge 309
Princeton 306
Ann Arbor 263
Dublin 217
Dong Ket 213
Beijing 204
Jacksonville 195
Boardman 190
Bologna 169
Lauterbourg 157
Westminster 129
Hefei 126
Nanjing 125
Padova 117
Los Angeles 116
Dallas 101
Abidjan 97
Tokyo 97
New York 92
Berlin 89
Lomé 84
San Diego 80
Helsinki 79
Haiphong 73
Shenyang 69
Buffalo 67
Saint Petersburg 62
Jinan 57
Sofia 57
Da Nang 52
Florence 49
Council Bluffs 48
Guangzhou 48
Redmond 48
Frankfurt am Main 47
Amman 46
Milan 45
Nanchang 45
Changsha 44
Dearborn 40
Des Moines 35
Hebei 35
Zhengzhou 33
Chicago 32
Redondo Beach 32
São Paulo 32
Mülheim 31
Tianjin 31
Turin 31
London 30
Medford 29
Nuremberg 29
Shanghai 29
Seoul 28
Falls Church 26
Munich 24
Biên Hòa 23
Norwalk 22
Rome 22
Bern 21
Bremen 21
Hải Dương 21
Phoenix 21
Redwood City 21
Abeokuta 20
The Dalles 20
Falkenstein 19
Hangzhou 19
Jiaxing 19
Mahé 19
Olalla 19
Amsterdam 17
Bühl 17
Ningbo 17
Verona 17
Wuhan 17
Atlanta 16
Moscow 16
Orem 16
Yubileyny 16
Baghdad 15
Montreal 15
Rio de Janeiro 15
Vienna 15
Benevento 14
Brussels 14
Totale 14.928
Salva come PNG Salva come JPEG
Nome #
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 478
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 390
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 294
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 257
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 257
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 253
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 250
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 244
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 238
A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. 232
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 227
Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study 220
Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department 219
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 216
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 213
Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study 213
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 213
Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy 211
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 210
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 203
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 201
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 198
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 197
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 193
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 189
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 189
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 187
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 186
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 183
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 182
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 181
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 180
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 180
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 177
Occult HBV infection in PBMCs of HIV+ individuals 175
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. 175
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 175
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 175
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study 172
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 171
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 171
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 170
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 170
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 170
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 168
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. 167
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 167
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 167
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program 167
Measles outbreak in the city of Bologna, December 2007 to May 2008 166
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 166
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. 165
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 165
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 163
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 162
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention. 161
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 161
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 161
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 159
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 159
Cmv-specific cell-mediated immunity in immunocompetent adults with primary cmv infection: A case series and review of the literature 159
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 158
Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. 157
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 155
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. 155
Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals 154
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 154
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 153
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients 153
105) ANTIVIRAL TREATMENT OF HEPATITIS C IN ITALIAN CHILDREN 151
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 151
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 149
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 149
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 147
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. 145
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 145
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 144
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 142
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 141
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? 141
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 141
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 140
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. 138
Hepatitis C Virus (HCV) genotipes in 373 Italian children with HCV infectiona: Changing distribution and correlation with clinical featurees and outcome. 136
Una rara complicanza infettiva in corso di trapianto ortotopico di fegato: gestione della peritonite tubercolare 134
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 134
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 134
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades 133
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 133
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 132
Terapia antiretrovirale con inibitori nucleosidici della trascrittasi inversa ed epatotossicità nei pazienti HIV positivi 131
Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus 131
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 130
Terapia della infezione da virus C 129
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 129
Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. 129
Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. 126
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 125
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 125
Out-of-hospital treatment of hepatitis c increases retention in care among people who inject drugs and homeless persons: An observational study 125
Totale 17.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.115
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021738 0 0 0 0 0 0 0 0 0 161 128 449
2021/20222.876 249 126 180 250 228 142 90 250 92 278 570 421
2022/20232.658 271 363 147 384 179 206 71 156 470 90 210 111
2023/2024678 58 125 43 54 49 141 40 55 29 33 20 31
2024/20252.828 118 510 236 230 471 150 181 101 28 159 73 571
2025/20266.462 663 478 637 479 812 429 721 376 1.394 473 0 0
Totale 22.930